

April 2026 PDL/DUR Board Meeting Minutes

Date: April 22, 2026

Members Present: Barnhill, Anglim, Blake, Brown, Caldwell, Forster, Harrison, Jost, Nauts, Oley, Rask

Members Absent: McGrane

Others Present: Shannon Sexauer, Dani Feist, Josh Surginer (DPHHS); Kathy Novak (Prime Therapeutics); Bahny, Blank (Mountain Pacific); and representatives from the pharmaceutical industry.

Public Comment: Speaker information is as follows:

- Jason Smith, Gilead - Epclusa®
- Kevin Schreur, ARS Pharmaceuticals - Neffy®
- Krystal Ngo, Arcutis Biotherapeutics, Inc. - Zoryve® Cream
- Sanaz Ziad, AstraZeneca - Breztri®
- Anna Allen, UCB - Bimzelx®
- Nissa Shaffi, Allergy & Asthma Network – epinephrine
- Mark Harmon, AbbVie - Mavyret® and Rinvoq®
- Christophe Langouet-Astrie, Boehringer Ingelheim - Jascayd®

In addition to the speakers, we had 10 written documents submitted to the Board for review. They were for the following:

- In the RED Group 3 we had 6 submissions: Bimzelx®, Otezla® from the *Cytokines/CAM Antagonists* category; Epclusa® from *Hepatitis C Agents*, Tezspire® from *Immunomodulators, Asthma*, and Zoryve® and Nemludio® from *Immunomodulators, Atopic Dermatitis*.
- In the BLUE Group 2 we had 3 submissions addressing the following: The Cystic Fibrosis Foundation recommendation for the *Antibiotics, Inhaled* category, Breztri Aerosphere® for the *COPD agents*, Neffy® for *Epinephrine, Self-Injected*.

We also had a letter from a provider requesting we return the Spravato® criteria for review of the counseling requirements. The Board voted to bring the Spravato® counseling requirements back to discuss at a future DUR Board meeting.

Meeting Minute Review: The meeting minutes from the March 18, 2026, PDL meeting were approved as written.

Department Update: No Department update.

PREFERRED DRUG LIST MEETING

Results of the Board review of Group 3 (Red category):

CLASS	DRUG NAME	2026 RECOMMENDATIONS	GRANDFATHERED
ANTIFUNGALS, ORAL	NI - Noxafil®	Must have terbinafine and fluconazole. Must have one of clotrimazole or nystatin. Continue PA criteria on ketoconazole.	No

		<i>The DUR Board requested criteria to be created for griseofulvin and to review existing criteria for ketoconazole. Both will be brought back to a future DUR Board meeting.</i>	
CYTOKINES & CAM ANTAGONISTS	NI - Omvoh®, Otezla/XR®, Rinvoq®, Simponi®, Tremfya®, Xeljanz/XR®, biosimilars - adalimumab, tocilizumab, ustekinumab	Therapeutic alternatives. Do not add anakinra (Kineret®) due to inferior efficacy and increased toxicity. Grandfather.	Yes
HEPATITIS C AGENTS	NI - Mavyret®	RIBAVIRINS - Class effect. PEGYLATED INTERFERONS - Do not add. ALL OTHERS - Therapeutic alternatives. Must have a pangenotypic agent. Continue with existing PA criteria. Grandfather.	Yes
IDIOPATHIC PULMONARY FIBROSIS	ND - Jascayd®	Therapeutic alternatives. Continue with existing PA criteria.	No
IMMUNOMODULATORS, ASTHMA	NI - Nucala®, Tezspire®	Therapeutic alternatives. Grandfathered class.	Yes
IMMUNOMODULATORS, ATOPIC DERMATITIS	ND - Anzupgo®, NI - Dupixent®, Zoryve®	Therapeutic alternatives. Continue PA criteria.	No

The Board reviewed the blue category in advance of the meeting. Kathy from Prime Therapeutics reported on new generics, updated indications, and drug availability changes in this category. This category of drugs has no new clinically significant information since the last review. Board recommendations for Group 2 (Blue category) from 2025 were retained. The recommendations are as follows:

CLASS	2026 RECOMMENDATIONS	Grandfathered
ACNE AGENTS	BENZOYL PEROXIDE COMBOS - Class effect. BENZOYL PEROXIDE AGENTS - Class effect. CLINDAMYCIN AGENTS - Class effect. SODIUM SULFACETAMIDE AGENTS - Class effect. TOPICAL RETINOIDS & COMBOS - Class effect. ERYTHROMYCIN TOPICAL - Class effect.	No
ANTI-ALLERGENS, ORAL	Continue with PA criteria.	No
ANTIBIOTICS, GI	Must have metronidazole and vancomycin.	No

ANTIBIOTICS, INHALED	Therapeutic alternatives.	No
ANTIBIOTICS, TOPICAL	Must have a mupirocin product.	No
ANTIBIOTICS, VAGINAL	Therapeutic alternatives.	No
ANTIFUNGALS, TOPICAL	Therapeutic alternatives for approved indications.	No
ANTI-HISTAMINES, MINIMALLY SEDATING	Class effect. Must have one single ingredient agent.	No
ANTI-NEOPLASTIC AGENTS, TOPICAL	Therapeutic alternatives.	No
ANTI-PARASITICS, TOPICAL	Therapeutic alternatives. Continue PA criteria.	No
ANTI-PYSORIATICS, TOPICAL	Class effect. Must have one topical formulation and a scalp formulation. Continue PA criteria.	No
ANTI-VIRALS, ORAL	HSV ANTI-VIRALS - Class effect. INFLUENZA ANTI-VIRALS - Must have both oseltamivir and baloxavir marboxil. <i>ANTI-VIRALS, COVID - May add Paxlovid.</i>	No
ANTI-VIRALS, TOPICAL	Class effect.	No
BLADDER RELAXANTS	Class effect. Must have one long-acting agent (either by half-life or dosage form), one anticholinergic, and one beta-3 receptor agonist.	No
BPH AGENTS	ALPHA BLOCKERS - Class effect. ANDROGEN HORMONE INHIBITORS/COMBOS - Class effect. PDE-5 for BPH - Class effect. Continue with PA criteria.	No
BRONCHODILATORS, BETA AGONISTS	BETA AGONIST, LONG-ACTING - Class effect. BETA AGONIST, SHORT-ACTING - Class effect.	No
CEPHALOSPORINS & RELATED AGENTS	2 nd GENERATION - Class effect. 3 rd GENERATION - Class effect.	No
COPD AGENTS	Class effect. Must have a nebulizer product and a long-acting combination product.	No
EPINEPHRINE, SELF- ADMINISTERED	Class effect.	No
FLUOROQUINOLONES, ORAL	2 nd GENERATION - Class effect. Must have ciprofloxacin. 3 rd GENERATION - Class effect.	No
GLUCOCORTICOIDS, INHALED	Class effect. Must have one HFA option.	No
GLUCOCORTICOIDS, ORAL	SHORT ACTING - cortisone, hydrocortisone - Therapeutic alternatives. INTERMEDIATE ACTING -	No

	methylprednisolone, prednisone, and prednisolone - Therapeutic alternatives. Must include a dosepak. LONG ACTING - betamethasone, dexamethasone - Therapeutic alternatives. BUDESONIDE - Must have one budesonide.	
IMMUNOMODULATORS, TOPICAL	Therapeutic alternatives.	No

IMMUNOSUPPRESSANTS	Must have an entity of azathioprine, cyclosporine, mycophenolate, sirolimus, and tacrolimus. Grandfather.	Yes
INTRANASAL RHINITIS AGENTS	NASAL STEROIDS - Class effect. NASAL ANTIHISTAMINES & OTHERS - Class effect.	No
LEUKOTRIENE MODIFIERS	Must have montelukast.	No
MACROLIDES & KETOLIDES	Class effect. Must have azithromycin, clarithromycin, and erythromycin.	No
METHOTREXATE AGENTS	Must have one oral and one injectable agent.	No
ROSACEA AGENTS, TOPICAL	Must have one metronidazole product.	No
SMOKING CESSATION	Must have a nicotine patch and either nicotine gum or lozenge. Must have varenicline.	No
STEROIDS, TOPICAL	LOW, MEDIUM, HIGH, and VERY HIGH POTENCY CLASSES - Class effect for each class; must have one cream and one ointment from each category.	No
TETRACYCLINES	Must have doxycycline.	No

There were no Group 1 (green category) drugs to review.

The meeting was adjourned at 2:16 p.m.

The final PDL meeting for 2026 will be held on May 20, 2026, at 1:00 p.m., in this same format.